Skip to main content
Premium Trial:

Request an Annual Quote

Sleepless in Waltham: Leach Leads GTC to Biopharm


Tim Leach started out as a physician, but he’s far from his tongue-depressor days. Hired to the newly created position of vice president of clinical and medical affairs at Genome Therapeutics, he’ll be providing guidance as the company shifts its sights from the pure genomics arena to biopharmaceuticals. That long-discussed shift was given a boost with the Ramoplanin project, a lead antibiotic candidate in-licensed from Biosearch Italia, which Leach will oversee.

“The company will continue with its genomics business,” Leach, 42, says of the Waltham, Mass.-based GTC. “[Genomics] will be obviously involved in drug discovery” and expects there to be a large need for sequencing bacterial genes and understanding their function as antibacterials come under the spotlight more and more.

Though Leach says it’s critical for GTC to continue developing its own discovery efforts, “it’s obviously important to be able to acquire near-term opportunities such as Ramoplanin which help drive the business forward,” he says.

Leach practiced as an infectious disease physician at the University of Medicine and Dentistry of New Jersey and at an East Orange, NJ, veterans’ hospital before venturing into industry. “What attracted me most to it was just the research efforts that are spearheaded by the pharmaceutical industry,” he says. He worked at Pharmacia and Upjohn on a new class of antibacterials that resulted in Zyvox, and later became medical director of Cubist Pharmaceuticals, “just down the road” from Genome Therapeutics.

He hasn’t been at GTC too long, but the company might already have noticed a marked increase in its coffee consumption. Leach is the father of an infant and a toddler: “The four-month-old makes my nights sleepless, and the two-year-old runs me ragged,” he says.

— Meredith Salisbury


The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.